Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine in DRC (DRC-EB-001)
NCT04152486Phase 3Unknown
- Sponsor
- London School of Hygiene & Tropical Medicine
- Start
- Nov 2019
- Primary completion
- Jan 2022
- Modality
- Viral Vector Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 3, open-label trial of zabdeno and Mvabea in Ebola virus disease (EVD), sponsored by London School of Hygiene & Tropical Medicine. Primary endpoint: Vaccination status in Ebola Virus Diseases cases and in EVD-negative controls at 2 years. Status: unknown.
02
Drugs
zabdenoMvabea
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT04152486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04152486.